urothelial carcinoma (advanced)

     

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

immune checkpoint inhibition

atezolizumab
IMvigor211 (IC2/3)atezolizumabchemotherapy2nd line, IC2/3 2nd line NCT02302807Risk of bias negative
IMvigor130 (monotherapy) ongoing atezolizumabcontrolfirst line 1st line NCT02807636Risk of bias ongoing
IMvigor010 ongoing atezolizumabcontroladjuvant adjuvant NCT02450331Risk of bias ongoing
IMvigor210 single-armatezolizumabnil1st and 2nd line 1st line 2nd line NCT02951767Exploratory -
avelumab
JAVELIN Bladder 100 ongoing avelumabcontrolNCT02603432Risk of bias ongoing
durvalumab
DANUBE ongoing durvalumab + tremelimumabchemotherapyfirst lineNCT02516241Low risk of bias ongoing
durvalumab phase 1/2 single-armdurvalumabnil2nd line 2nd line Exploratory -
nivolumab
CHECKMATE 901A ongoing nivolumab + chemotherapychemotherapyfirst line 1st line NCT03036098Risk of bias ongoing
Checkmate 275 single-armnivolumabnil2nd line 2nd line NCT02387996Exploratory -
CheckMate 274 ongoing nivolumabplacebofirst line adjuvant NCT02632409Low risk of bias ongoing
CHECKMATE 274A ongoing nivolumabplaceboadjuvant adjuvant NCT02632409Low risk of bias ongoing
pembrolizumab
KEYNOTE-045, 2017pembrolizumabchemotherapy2nd line 2nd line NCT02256436Risk of bias suggesting